ClinicalTrials.gg
Active, not recruitingNCT03894423Updated Apr 17, 2026

Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery

An observational study in CAD, Atheroscleroses, Coronary and Computed Tomography, sponsored by Stanford University. Active, not recruiting at 3 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Stanford University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Stanford University — none open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Stanford University.

Started
2019
the only one that year
Observational
4 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Coronary Artery Disease by Stanford University, this one is the only one that started in 2019, is one of 4 observational ones, and was the 8th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 11 studies in Coronary Artery Disease by Stanford University is open now. The open studies under Coronary Artery Disease, anywhere →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Coronary Artery Disease by Stanford University as a file.
02

Study summary

Apply CT angiography, CT perfusion imaging and advanced image processing techniques to improve revascularization decision-making and surgical strategies in patients undergoing coronary artery bypass graft surgery.

Read the detailed description

The objective of this study is to integrate noninvasively acquired anatomical and functional information to develop clinically applicable tools for meaningful per-vessel revascularization decisions. The decisions will be based on quantitative lesion-specific ischemia and viability and flow simulations. These will be based on CT anatomy enhanced with a function for prediction of hemodynamic improvement after CABG.

Aim 1: Predict restoration of myocardial perfusion from coronary artery bypass graft surgery. The investigators will perform cardiac CT before and after CABG and measure absolute changes in myocardial perfusion as the functional outcome of CABG. The investigators will investigate clinical, surgical and imaging variables in association with post-CABG perfusion improvement on a per-vessel and per-patient level.

Aim 2: Non-invasively quantify vessel-specific ischemia for meaningful CABG decisions.

The investigators will develop and validate tools for assessment of vessel-specific ischemia and viability. The investigators will assess the potential impact of CT guided CABG by comparing the per-vessel need for grafting with standard care.

Aim 3: Predict CABG benefit through multi-parameter flow simulations Hypothesis: Integration of myocardial perfusion and viability can improve flow simulation models to predict CABG outcome. The investigators will develop new computational fluid dynamics models enriched with functional parameters and explore the potential of virtual grafting to improve hemodynamic outcomes.

03

Conditions studied

  • CAD
  • Atheroscleroses, Coronary
  • Computed Tomography
  • Coronary Artery Bypass
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients scheduled to undergo coronary bypass graft surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned elective CABG for coronary artery disease.
  • CABG is the primary indication for surgery (but may include treatment of mild-moderate valvular disease).
  • Age: ≥40 years.

Exclusion criteria

Exclusion Criteria:

  • Technical feasibility of the cardiac CT exams: redo-CABG, significant arrhythmia/mal-conduction, congenital conditions, severe valvular disease or cardiomyopathy (to the extent that the CT acquisition is technically challenged), inadequate understanding of the English language (to provide consent or follow instructions during the exams).
  • Overall safety: unstable clinical condition (clinical heart failure, unstable angina, myocardial infarction \<1 month prior).
  • Radiation risk: pregnancy (cannot be ruled out), body weight >100kg.
  • CT contrast medium-related: known allergy, renal failure
  • Vasodilator related: known allergy, bronchial asthma requiring daily use of bronchodilators, Mobitz II or 3rd degree AV block, sick sinus node disease, carotid artery narrowing, severe aortic stenosis or LVOT narrowing, systolic blood pressure below 90mmHg, (continued) use of dipyridamole or aminophylline.
  • Inability to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in myocardial blood flow from baseline measured by cardiac CT

    Myocardial blood flow will be measured by dynamic stress CT perfusion imaging before and 2 months after CABG. The primary endpoint is the difference MBF values between both examinations, per coronary distribution.

    Time frame: 2 Months

Secondary outcomes

  1. Bypass graft obstruction by cardiac CT

    The presence of bypass grafts obstruction will be assessed on CT angiography

    Time frame: 2 Months

  2. Change in angina pectoris assessed by SAQ

    Severity of anginal complaints will be assessed using the Seattle Angina Questionnaire before and 1 year after CABG.

    Time frame: 1 Year

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — No current plan to share data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2026, 91 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 91 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2019
First posted
Mar 28, 2019
StartActual
May 1, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03894423
Responsible party
Koen Nieman (Professor, Stanford University) — Principal investigator
First posted
Mar 28, 2019
Start date
May 1, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 17, 2026

Study contacts

Koen Nieman, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion